Canadian leukemia study

A Canadian study may pave the way for a new treatment for acute myeloid leukemia, or AML , and a solution to the high rate of relapse.

Researchers from a number of centres in Toronto have identified a protein interaction that limits the immune response to AML and provides a way to disrupt it.

The team is working to develop leukemia treatments based on their findings.

Although AML is a relatively rare disease, it’s typically fatal within weeks or months if left untreated.